SCHEMBL9334941

SCHEMBL9334941

CNc1ccc(Nc2ccc(C)cc2S(=O)(=O)O)c2c1C(=O)c1ccccc1C2=O.[NaH]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GNG2 P59768 4/20 0.50
▸ GNB1 P62873 4/20 0.50
▸ P2RY4 P51582 6/20 0.47
▸ P2RY2 P41231 5/20 0.47
▸ MAPT P10636 4/20 0.44
▸ TDP1 Q9NUW8 3/20 0.44
▸ MAPK1 P28482 3/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ EGFR P00533 1/20 0.44
▸ PABPC1 P11940 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ RECQL P46063 1/20 0.43
▸ CASP6 P55212 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9172504 0.99 GNG2 (0.51) GNG2GNB1P2RY4P2RY2MAPT
SCHEMBL462730 0.95 P2RY4 (0.51) GNG2GNB1P2RY4P2RY2MAPT
SCHEMBL344329 0.94 P2RY4 (0.52) GNG2GNB1P2RY4P2RY2MAPT
SCHEMBL29678418 0.94 P2RY4 (0.52) GNG2GNB1P2RY4P2RY2MAPT
SCHEMBL462731 0.92 P2RY4 (0.51) GNG2GNB1P2RY4P2RY2MAPT
SCHEMBL17637566 0.90 P2RY4 (0.49) GNG2GNB1P2RY4P2RY2MAPT
SCHEMBL185514 0.89 P2RY2 (0.47) GNG2GNB1P2RY4P2RY2MAPT
SCHEMBL23787875 0.89 P2RY4 (0.60) GNG2GNB1P2RY4P2RY2MAPT
SCHEMBL2343045 0.88 CYP1A2 (0.51) GNG2GNB1P2RY4P2RY2MAPT
SCHEMBL29678417 0.88 MEN1 (0.47) GNG2GNB1P2RY4P2RY2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0525073-B1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA DU PONT (US) 1994-05-25 — — EP claimed
EP-0525073-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA. DU PONT (US) 1993-02-03 — — EP claimed
WO-1991015954-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-31 — — WO claimed
WO-2022188373-A1 METHOD FOR DETECTING WATER-SOLUBLE ANIONIC SYNTHETIC PIGMENT IN FOOD 广州市食品检验所(广州市酒类检测中心) 2022-09-15 — — WO disclosed
US-20210115489-A1 NOVEL MEDIATOR KIKKOMAN CORPORATION (JP) 2021-04-22 — — US disclosed
EP-3780207-A1 NOVEL MEDIATOR Kikkoman Corporation (JP) 2021-02-17 — — EP disclosed
CN-112042026-A Novel mediator 龟甲万株式会社 2020-12-04 — — CN disclosed
WO-2019198359-A1 NOVEL MEDIATOR キッコーマン株式会社 2019-10-17 — — WO disclosed
EP-0525073-B1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA DU PONT (US) 1994-05-25 — — EP disclosed
EP-0525073-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA. DU PONT (US) 1993-02-03 — — EP disclosed
WO-1991015954-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115489-A1 NOVEL MEDIATOR MPO, EPX, LPO GNG2 2481/4885GNB1 3346/4885P2RY4 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback